Search Results
Your search for ,OUr matches 10724 pages
Showing 6551 - 6600Low-Grade Gliomas: Understanding the New Treatment Paradigm
Diffuse infiltrating low-grade gliomas include oligodendrogliomas and astrocytomas and account for about 5% of all primary brain tumors. Treatment strategies for these low-grade gliomas in adults have recently changed, as detailed in a recent review in the Journal of Oncology Practice.1 The...
Royal Swedish Academy of Sciences Inaugural Sjöberg Prize Awarded to James P. Allison, PhD, and Tony Hunter, PhD
The Royal Swedish Academy of Sciences (RSAS) has decided to award the inaugural Sjöberg Prize 2017 to James P. Allison, PhD, Professor and Vivian L. Smith Distinguished Chair in Immunology at The University of Texas MD Anderson Cancer Center, and Tony Hunter, PhD, American Cancer Society...
Scientists Tackle Next Set of Immunotherapy Challenges
Cancer immunotherapy is about to get much more complicated. Just as oncologists are becoming familiar with checkpoint inhibitors and their growing indications, they will eventually be challenged with using them in novel combinations and in new tumor types. This will be the fruit that comes from...
Close to Home: Dr. Rick Boulay’s Experience With Cancer Survivorship and Caregiving
Richard ‘Rick’ Boulay, MDChief of Gynecologic Oncology Institution: Lehigh Valley Health Network Member since: 2016 Three years ago, Richard ‘Rick’ Boulay, MD, Chief of Gynecologic Oncology at Lehigh Valley Health Network, walked onto the stage at TEDx Lehigh River and confronted his audience...
Can Antiviral Therapy Prevent Liver Cancer in Patients With Chronic Hepatitis?
Chronic viral hepatitis is a major causative factor for hepatocellular carcinoma, but antiviral therapy might reduce the incidence of hepatocellular carcinoma by preventing or eliminating chronic hepatitis infections, according to Adrian M. Di Bisceglie, MD, Professor of Internal Medicine at Saint ...
Study Identifies How Cancer Cells May Develop Resistance to FGFR Inhibitors
A new study by researchers at The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC– James) has identified a mechanism by which cancer cells develop resistance to a class of drugs called fibroblast growth...
Honoring the Life of Nancy E. Armitage
The University of Nebraska community mourns the loss of dedicated community leader and volunteer Nancy E. Armitage of Omaha. She died February 27, 2017, from complications associated with pancreatic cancer. Nancy is remembered for the support and encouragement she offered to others over the years...
Cervical Cancer Mortality Is Higher and Racial Disparity Wider Than Previously Reported
Cervical cancer mortality rates were significantly higher, particularly among black women, when national data were corrected to exclude women who have had hysterectomies. For black women, the cervical cancer mortality rate rose from 5.7 to 10.1 per 100,000 when corrected for hysterectomy, an...
Immunotherapy for Head and Neck Cancer: ‘The Fourth Modality Has Arrived’
“This is a big deal. This is going to change all of oncology, not just head and neck cancer,”1 Tanguy Seiwert, MD, remarked following a summary by Jeffrey Sosman, MD, on advances in immunotherapy for treating cancer.2 Dr. Sosman, Director of the Melanoma Program and Clinical Director of Cancer...
Immunotherapy Challenges in Lung Cancer: From Patient Selection to Clinical and Financial Toxicity
Immunotherapy has been a major advance in lung cancer, but it is not without its challenges, according to Sanjay Popat, PhD, FRCP, a consultant medical oncologist and reader in cancer medicine at the Royal Marsden Hospital, London, UK. He reviewed some of the challenges pertaining to the use of...
Potential Biomarker of Recurrent Venous Thromboembolism in Patients Receiving Anticoagulants
In a biomarker analysis of the CATCH trial reported in the Journal of Clinical Oncology, Alok A. Khorana, MD, of the Cleveland Clinic, and colleagues found that elevated circulating tissue factor levels were associated with an increased risk of recurrent venous thromboembolism in cancer patients on ...
Expert Point of View: Kevin C. Oeffinger, MD
Kevin C. Oeffinger, MD, Director of the Adult Long-Term Follow-up Program at Memorial Sloan Kettering Cancer Center, New York, highlighted the typical fat distribution of this population while noting the limitations of standard criteria for metabolic syndrome, which include waist circumference....
Platinum Study Finds High Risk of Metabolic Syndrome in Testicular Cancer Survivors
A multicenter study of North American testicular cancer survivors treated with platinum-based chemotherapy has found a high prevalence of metabolic syndrome, a cluster of cardiovascular risk factors that doubles the risk of cardiovascular disease.1 According to the results of this trial,...
Building a Multidisciplinary Model of Care for Cancer Survivors
Last year’s inaugural Cancer Survivorship Symposium stressed the importance of bringing together the fields of medical oncology and primary care to ensure a coordinated effort to help patients with cancer transition to long-term survivorship care. Building on that goal, the 2017 Cancer Survivorship ...
ASCO and NCCN to Collaborate on Guidelines on Management of Immunotherapy Side Effects
ASCO and the National Comprehensive Cancer Network® (NCCN®) have announced a joint collaboration to publish practical clinical guidance on the management of side effects caused by immunotherapy. This novel collaboration aims to rapidly support improved quality of care for the growing number of...
Cleveland Clinic Opens New Taussig Cancer Center
The new Cleveland Clinic Taussig Cancer Center began welcoming patients on March 6, 2017. The 377,000 square-foot facility houses all outpatient cancer treatment services in one location, with the center’s team of medical and radiation oncologists, surgeons, nurses, genetic counselors, social...
IASLC Statement Regarding Philip Morris’ Smoke-Free Future
On February 1, 2017, the International Association for the Study of Lung Cancer (IASLC) issued the following statement: According to its own public reports, in 2016 Phillip Morris manufactured 800 billion cigarettes. Thus, [IASLC] views with some skepticism Philip Morris’ recent statement...
CAR T-Cell Therapy Emerging in Multiple Myeloma
For patients with multiple myeloma, chimeric antigen receptor (CAR) T-cell therapy is gaining ground in pilot studies. At the 2016 American Society of Hematology (ASH) Annual Meeting & Exposition, researchers presented their latest findings for this innovative therapy, which has proven...
Fox Chase–Temple University Hospital Bone Marrow Transplant Program Awarded FACT Accreditation
The Fox Chase–Temple University Hospital Bone Marrow Transplant Program has received internationally recognized accreditation by the Foundation for the Accreditation of Cellular Therapy (FACT) at the University of Nebraska Medical Center. By demonstrating compliance with the FACT-JACIE...
A Decade of Lessons Learned From EGFR-Targeted Therapy
To summarize the lessons learned from the development of epidermal growth factor receptor (EGFR)-targeted therapy, one only has to go back about 10 years, according to Frances A. Shepherd, MD, Scott Taylor Chair in Lung Cancer Research at Princess Margaret Cancer Centre and Professor of Medicine at ...
Update on Overall Survival for Newly Diagnosed Patients With Metastatic Pancreatic Cancer
Although “treatment advances” and “precision medicine” are today’s buzz words in oncology, they don’t apply equally to all malignancies. For instance, median overall survival for newly diagnosed patients with metastatic pancreatic cancer has not improved much over the past 20 years, according to...
Expert Point of View: Susan F. Slovin, MD, PhD
Formal discussant for the presentation of SWOG S9921 results, Susan F. Slovin, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, New York, said there were some important points to understand about this “vintage” trial. “The trial was designed 20 years ago, and the view is...
Make Vaccination Great Again
Human papillomavirus (HPV) is the most common sexually transmitted infection worldwide. It affects 80% of individuals, with the initial infection usually occurring between the ages of 15 and 24. Persistent infection with oncogenic HPV genotypes, primarily 16 and 18, is the cause of virtually all...
How Stupid Cancer Is Building a Support Community for AYA Survivors
In 1995, Matthew Zachary, an aspiring concert pianist and composer, was en route to graduate school to study film composition when he lost all fine-motor coordination in his left hand, was diagnosed with pediatric brain cancer (medulloblastoma), told he would never play again, and was given 6...
FALCON Trial Informs the Evolving Role of Fulvestrant in Advanced Hormone Receptor–Positive Breast Cancer
Endocrine therapy for breast cancer has evolved over the years. Initial endocrine therapies consisted of ablative procedures (oophorectomy, adrenalectomy, and hypophysectomy). With the availability of pharmaceutical estrogens, progestins, and androgens, ablative procedure utilization begin to...
Nivolumab in Previously Treated Unresectable Metastatic Squamous Cell Carcinoma of the Anal Canal
In a phase II trial reported in The Lancet Oncology, Morris et al found that nivolumab (Opdivo) was active in previously treated unresectable metastatic squamous cell carcinoma of the anal canal. This malignancy is associated with human papillomavirus (HPV) infection, with the rationale for...
Barriers to Clinical Trial Accrual Include Trial Sponsorship and Time to Enrolling First Patient, Study Finds
A study by researchers from The University of Texas MD Anderson Cancer Center investigating factors associated with slow participant accrual into phase I to III cancer clinical trials at their institution has found trials initiated through national cooperative groups and the time taken from trial...
Comparison of Pharmaceutical, Psychological, and Exercise Treatments for Cancer-Related Fatigue
Exercise and/or psychological therapy may work better than medications to reduce cancer-related fatigue and should be recommended first to patients, according to a Wilmot Cancer Institute-led study published by Mustian et al in JAMA Oncology. “If a [patient with cancer] is having trouble...
Two Migration Proteins Boost Predictive Value of Pancreatic Cancer Biomarker
Adding two blood-borne proteins associated with cancer cell migration increases the predictive ability of the current biomarker for pancreatic cancer to detect early-stage disease, a research team from The University of Texas MD Anderson Cancer Center reported in a study by Balasenthil et al in the ...
Study Finds Sharp Rise in Colon and Rectal Cancers in Young Adults
Although the overall incidence rate of colorectal cancer in the United States has been declining rapidly since the mid-1980s, the decrease has been in older adults. During this same period, incidence rates have been increasing sharply for adults younger than age 50, finds a study by the American...
Poor Diet During Adolescence/Early Adulthood and Risk for Premenopausal Breast Cancer
Although adolescence is a highly susceptible time for mammary carcinogenesis, few prospective studies have examined the role of adolescent diet and breast cancer risk. Now, a study investigating the association of an adolescent and early adulthood dietary pattern that promotes chronic inflammation...
ASCO Quality Care 2017: Study Examines Cancer Center Websites’ Information on Breast Cancer Treatment, Outcomes
As an increasing number of patients look to the internet for cancer information, researchers from the University of Alabama found that the websites of many National Cancer Institute (NCI)-designated cancer centers lack sufficient information to help patients with breast cancer understand all their...
ASCO Quality Care 2017: In-House Specialty Pharmacy at Cancer Center Improves Quality of Care, Reduces Medical Errors
An influx of new oral cancer drugs provides patients with a more convenient and less invasive way to take medication, but such treatments are often associated with adherence challenges and medical errors. New research shows that the addition of an in-house specialty pharmacy at a cancer center in...
Leader in Cancer Care and Prevention, Charles A. LeMaistre, MD, Dies
In 1978, Charles A. “Mickey” LeMaistre, MD, was named President of The University of Texas MD Anderson Cancer Center. During his 18-year tenure, MD Anderson became a world leader in outpatient care for cancer patients and the nation’s largest ambulatory treatment and surgery programs in cancers....
Remembering Stephen K. Carter, MD, and His National and International Impact on Early Drug Development
Stephen K. Carter, MD, a renowned oncologist who held a variety of executive positions in the pharmaceutical industry and played a major role in the research and development of many widely used cancer and AIDS drugs, died on November 14, 2016, after a long battle against multiple systems atrophy....
Rucaparib in Relapsed Platinum-Sensitive High-Grade Ovarian Cancer
In part 1 of the phase II ARIEL2 trial reported in The Lancet Oncology, Elizabeth M. Swisher, MD, of the University of Washington, and colleagues found that the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib was associated with prolonged progression-free survival among patients with...
Harold H. Tara, Jr, MD, Appointed Medical Director of Smilow Care Centers in Connecticut
Harold H. Tara, Jr, MD, has been appointed Medical Director of the Smilow Cancer Hospital Care Centers in Trumbull and Fairfield, Connecticut. Dr. Tara’s leadership will ensure that the centers continue to offer patients the best care available, along with the latest treatment options through...
Researchers Use Cardiomyocytes to Create Index of Cardiotoxicity of Tyrosine Kinase Inhibitors
Researchers at the Stanford University School of Medicine used heart muscle cells made from stem cells to rank commonly used chemotherapy drugs based on their likelihood of causing lasting heart damage in patients. Tyrosine kinase inhibitors can be an effective treatment for many types of cancers, ...
Bright Future for Osimertinib in EGFR T790M–Positive Lung Cancer
The AURA3 study—reported by Mok and colleagues and reviewed in this issue of The ASCO Post—confirms the dramatic activity of osimertinib (Tagrisso) in patients with advanced epidermal growth factor receptor (EGFR)-mutant non–small cell lung cancer (NSCLC) and acquired resistance to prior EGFR...
American Cancer Society Awards Medal of Honor to Three Cancer Researchers
Three outstanding individuals have been honored with the American Cancer Society Medal of Honor Award. The Medal of Honor is awarded to those who have made the most valuable contributions and impact in saving more lives from cancer through basic research, clinical research, and cancer control....
Study Finds Children, Parents Overreport Adherence to Leukemia Treatment
New research suggests that young patients with acute lymphocytic leukemia (ALL)—the most common type of pediatric cancer—and their parents are likely to report to their physician that they took more of their anticancer medication than they actually did. The study, published by Landier et al in...
Clinical Trial to Explore Genetic Cancer Test to Offer Safe Thyroid-Preserving Surgery
University of Pittsburgh School of Medicine scientists and doctors are embarking on the first-ever clinical trial to determine whether a genetic test they pioneered could successfully spare patients with nonaggressive thyroid cancer from complete removal of their thyroid. Such thyroid-preserving...
Update on Fertility Outcomes Among Survivors of Childhood Cancer
“Estimates suggest that by the year 2020, there will be over 500,000 adult survivors of childhood cancer in the United States,” Daniel A. Mulrooney, MD, MS, of the Division of Cancer Survivorship, St. Jude Children’s Research Hospital, Memphis, reported at the 10th Oncofertility Conference in...
CCF Researcher Spotlight: David M. Waterhouse, MD, MPH
The Conquer Cancer Foundation (CCF) is excited to partner with David M. Waterhouse, MD, MPH, of Oncology Hematology Care in Cincinnati, Ohio, to increase awareness for the Foundation’s Campaign to Conquer Cancer. The Conquer Cancer Foundation was proud to support Dr. Waterhouse with a Young...
ASCO Submits Comments on NIH Data-Sharing Request for Information
Earlier this year, ASCO submitted comments to the National Institutes of Health (NIH) in response to a Request for Information on data-sharing and management (NOT-OD-17-015). In the comment letter, ASCO expressed support for the NIH’s efforts to develop a framework and strategies for data-sharing ...
$1.8M Grant to Wenwei Hu, PhD, to Aid Exploration of Role of Chronic Stress in Cancer Development
A 5-year, $1.8 million grant from the National Cancer Institute awarded to Rutgers Cancer Institute of New Jersey resident research member Wenwei Hu, PhD, will support research to further elucidate the mechanisms behind the most frequently mutated gene in human tumors—p53. The aim is to explore...
Expert Point of View: Jose Leis, MD, PhD
Jose Leis, MD, PhD, of the Mayo Clinic in Arizona, commented on the promise of checkpoint inhibitors in Richter transformation. “At Mayo, we have treated more than 30 patients with programmed cell death protein 1 (PD-1) blockade. We do see that chronic lymphocytic leukemia (CLL) has low expression ...
Phase II Studies Evaluate New Approaches in Richter Transformation
Despite advances in treating chronic lymphocytic leukemia (CLL), the 5% to 10% of patients who develop Richter transformation continue to have poor outcomes. For these patients, median progression-free survival is approximately 6 months, and median overall survival is about 8 months. Phase II...
Exploring the Opportunities and Challenges of Seamless Drug Development
The traditional three-phase clinical trial process for testing new drugs does not necessarily make sense when it comes to targeted therapies, according to many experts, including regulators, academic researchers, industry chief executive officers, and patient advocates alike. Instead of three...
Payers Weigh the Implications of Multigene Testing Coverage
Innovation in precision medicine has introduced an amalgam of testing options, of which hereditary cancer panels—multigene tests—are a major component. Additionally, the importance of inherited cancer genomics was further bolstered by former President Barack Obama’s Precision...
